← SynDRA
PACRITINIB
SynDRA canonical compound SYN0029224 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | CDK2 | FLT3 | JAK1 | JAK2 | JAK3 |
|---|
| Mechanism of action | FLT3 inhibitor | JAK inhibitor |
|---|
All known targets
- FLT3
- JAK3
- JAK2
- ACVR1
- JAK1
- IRAK1
- MAP4K1
- MAP4K4
- MAPK8
- NEK9
- NQO2
- PDGFRB
Mechanisms of action (all sources)
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- FLT3 INHIBITOR
- Tyrosine-protein kinase receptor FLT3 inhibitor
- ACVR1 INHIBITOR
- Activin receptor type-1 inhibitor
- IRAK1 INHIBITOR
- Interleukin-1 receptor-associated kinase 1 inhibitor
- JAK inhibitor
- FLT3 MODULATOR
- JAK3 MODULATOR
Drug classes
- Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 1A2 Inhibitors
- Cytochrome P450 3A4 Inhibitors
- P-Glycoprotein Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Janus Kinase Inhibitors
- Organic Cation Transporter 1 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- pacritinib citrate
- vonjo
- SB1518
- SB-1518
- ONX-0803
- JAK inhibitor (alone or in combination)s
- Pacritinib (SB1518)
- SB 1518
- Pacritinib(SB1518)
- ONX 0803
- G22N65IL3O
- Vonjo
- 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
- 14,19-Dioxa-5,7,27-triazatetracyclo(19.3.1.12,6.18,12)heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-(2-(1-pyrrolidinyl)ethoxy)-, (16E)-
- CHEMBL2181330
- Pacritinib [INN]
- Pacritinib (USAN/INN)
- Pacritinib [USAN:INN]
- PACRITINIB [USAN]
- PACRITINIB [WHO-DD]
- SB-1518 TFA salt
- UNII-G22N65IL3O
- GTPL7793
- SCHEMBL1108221
- CHEMBL2035187
- SCHEMBL22819303
- EX-A240
- DTXSID801045679
- AMY23364
- BAX 2201
- BCP09091
- BDBM50210177
- BDBM50400312
- MFCD22572772
- NSC759674
- NSC781626
- s8057
- AKOS037515687
Look up PACRITINIB in the interactive SynDRA portal →